Asfotase alfa COVID-19 PAG message
At the asfotase alfa (Strensiq) National Authorisation Panel (NAP) meeting in December 2020 the members discussed the impact of COVID-19 on patients’ clinical outcomes (test results) in 2020. Lockdown measures and shielding can lead to a reduction in physical activity which can in turn affect clinical outcomes such as weight and ambulation (the ability to walk). Considering the new lockdown measures currently in place in England, we would like to highlight to patients and their carers that shielding is not necessary for Hypophosphatasia (HPP) patients (unless a patient has another medical condition(s) which requires them to shield as detailed in the UK government guidelines). We encourage patients to be active and continue physical activity where it is safe and possible to do so. This advice is supported by the HPP clinical experts on the NAP. If you have any questions or concerns about this guidance please do not hesitate to contact us.